Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: Examining a more efficient trial design

Neurology

Volumn 77, Issue 10, 2011, Pages 973-979

  Miller, R G ^a   Moore, D H ^a   Forshew, D A ^a   Katz, J S ^a   Barohn, R J ^a   Valan, M ^a   Bromberg, M B ^a   Goslin, K L ^a   Graves, M C ^a   McCluskey, L F ^a   McVey, A L ^a   Mozaffar, T ^a   Florence, J M ^a   Pestronk, A ^a   Ross, M ^a   Simpson, E P ^a   Appel, S H ^a  

^a Forbes Norris MDA/ALS Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LITHIUM CARBONATE; MINOCYCLINE; PLACEBO; RILUZOLE;

AMYOTROPHIC LATERAL SCLEROSIS; ANOREXIA; ARTICLE; BODY WEIGHT; CONFUSION; CONTROLLED STUDY; DEHYDRATION; DEPRESSION; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG SAFETY; DRUG SCREENING; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; ENDOTRACHEAL INTUBATION; FEVER; FOLLOW UP; FORCED VITAL CAPACITY; HUMAN; JOINT SWELLING; LETHARGY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; TREATMENT DURATION; TREMOR; UNSPECIFIED SIDE EFFECT; URINARY URGENCY; WEAKNESS; WEIGHT REDUCTION; ADULT; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; FEMALE; MALE; MASS SCREENING; METHODOLOGY; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; AMYOTROPHIC LATERAL SCLEROSIS; DISEASE PROGRESSION; FEMALE; HUMANS; LITHIUM CARBONATE; MALE; MASS SCREENING; MIDDLE AGED; RESEARCH DESIGN; YOUNG ADULT;

EID: 80055073951     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31822dc7a5     Document Type: Article

References (21)

1. Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009;73:1218-1226.
2. Fornai F, Longone P, Cafaro L, et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2008;105:2052-2057. (Pubitemid 351439463)
3. Fornai F, Longone P, Ferrucci M, et al. Autophagy and amyotrophic lateral sclerosis: the multiple roles of lithium. Autophagy 2008;4:527-530. (Pubitemid 351705154)
4. Sarkar S, Floto RA, Berger Z, et al. Lithium induces autophagy by inhibiting inositol monophosphatase. J Cell Biol 2005;170:1101-1111. (Pubitemid 41362642)
5. Sarkar S, Rubinsztein DC. Inositol and IP3 levels regulate autophagy: biology and therapeutic speculations. Autophagy 2006;2:132-134.
6. Czaplinski A, Haverkamp LJ, Yen AA, Simpson EP, Lai EC, Appel SH. The value of database controls in pilot or futility studies in ALS. Neurology 2006;67:1827-1832. (Pubitemid 44900761)
7. Gordon PH. A placebo arm is not always necessary in clinical trials of amyotrophic lateral sclerosis. Muscle Nerve 2009;39:858-860.
8. Simmons Z. Can we eliminate placebo in ALS clinical trials? Muscle Nerve 2009;39:861-865.
9. Groeneveld GJ, Veldink JH, van der Tweel I, et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol 2003;53:437-445. (Pubitemid 36373255)
10. Kaufmann P, Thompson JL, Levy G, et al. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol 2009;66:235-244.
11. Aggarwal SP, Zinman L, Simpson E, et al. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, doubleblind, placebo-controlled trial. Lancet Neurol 2010;9: 481-488.
12. Chio A, Borghero G, Calvo A, et al. Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dosefinding trial. Neurology 2010;75:619-625.
13. Gordon PH, Moore DH, Miller RG, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007;6:1045-1053. (Pubitemid 350116691)
14. Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:293-299.
15. Robbins RA, Simmons Z, Bremer BA, Walsh SM, Fischer S. Quality of life in ALS is maintained as physical function declines. Neurology 2001;56:442-444. (Pubitemid 32172865)
16. Shefner JM, Cudkowicz ME, Schoenfeld D, et al. A clinical trial of creatine in ALS. Neurology 2004;63:1656-1661. (Pubitemid 39507584)
17. Cudkowicz ME, Shefner JM, Schoenfeld DA, et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol 2006;60:22-31.
18. Miller R, Bradley W, Cudkowicz M, et al. Phase II/III randomized trial of TCH346 in patients with ALS. Neurology 2007;69:776-784. (Pubitemid 47300935)
19. Cudkowicz ME, Katz J, Moore DH, et al. Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010;11:259-265.
20. NINDS NET-PD Investigators. A randomized, doubleblind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 2006;66:664-671.
21. Zhang S, Cao J, Ahn C. Calculating sample size in trials using historical controls. Clin Trials 2010;7:343-353.